PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CE-224,535
Drug: Placebo

First Posted Date: 2008-03-04

Last Posted Date: 2022-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT00628095

Locations: 🇺🇸
University Physicians, Columbia, Missouri, United States
🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States
🇺🇸
New Horizons Clinical Research, Cincinnati, Ohio, United States

and more 23 locations

Genotropin Treatment In Very Young Children Born Small For Gestational Age

Phase 3

Completed

Conditions: Infant, Small for Gestational Age

Interventions: Drug: Genotropin (PN-180,307) Somatropin
Drug: Control-no treatment

First Posted Date: 2008-03-03

Last Posted Date: 2014-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00627523

Locations: 🇮🇹
Policlinico Universitario, Istituto di Clinica Pediatrica, Messina, Italy
🇸🇪
Drottning Silvias Barn och Ungdomssjukhus, Göteborg, Sweden
🇮🇹
Dipartimento di Medicina Pediatrica, UO di Endocrinologia e Diabetologia, Roma, Italy

and more 14 locations

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Cabergoline
Other: Placebo

First Posted Date: 2008-02-29

Last Posted Date: 2011-04-25

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00627003

A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Phase 2

Terminated

Conditions: Diabetic Neuropathies

Interventions: Drug: Placebo
Drug: [S,S]-Reboxetine

First Posted Date: 2008-02-28

Last Posted Date: 2019-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 330

Registration Number: NCT00625833

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: cabergoline
Drug: levodopa

First Posted Date: 2008-02-28

Last Posted Date: 2008-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 361

Registration Number: NCT00625547

Locations: 🇨🇭
Pfizer Investigational Site, Zürich, Switzerland

Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy

Phase 3

Terminated

Conditions: Infant, Small for Gestational Age
Growth Hormone Therapy

Interventions: Drug: Somatropin

First Posted Date: 2008-02-28

Last Posted Date: 2012-02-29

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00625872

Locations: 🇩🇪
Pfizer Investigational Site, Muenchen, Germany

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Phase 4

Terminated

Conditions: Aspergillosis

Interventions: Drug: voriconazole
Drug: anidulafungin

First Posted Date: 2008-02-21

Last Posted Date: 2010-02-15

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00620074

Locations: 🇺🇸
Pfizer Investigational Site, Fort Worth, Texas, United States

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: PH-797804

First Posted Date: 2008-02-21

Last Posted Date: 2018-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00620685

Locations: 🇺🇸
Pfizer Investigational Site, Duncansville, Pennsylvania, United States

Complicated Skin and Skin Structure Infections

Phase 3

Completed

Conditions: Cellulitis
Skin Infection
Abscess

Interventions: Drug: Meropenem
Drug: Imipenem-cilastatin

First Posted Date: 2008-02-21

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 1000

Registration Number: NCT00619710

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-00734200 30 mg QD
Drug: Placebo
Drug: PF-00734200 20 mg QD

First Posted Date: 2008-02-18

Last Posted Date: 2011-06-27

Lead Sponsor: Pfizer

Target Recruit Count: 289

Registration Number: NCT00618007

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy